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Abstract
Huntington’s disease (HD) patients and mouse models show learning and memory impairment associated with
hippocampal dysfunction. The neuronal nitric oxide synthase/3',5'-cyclic guanosine monophosphate (nNOS/cGMP)
pathway is implicated in synaptic plasticity, and in learning and memory processes. Here, we examined the nNOS/
cGMP pathway in the hippocampus of HD mice to determine whether it can be a good therapeutic target for cognitive
improvement in HD. We analyzed hippocampal nNOS and phosphodiesterase (PDE) 5 and 9 levels in R6/1 mice,
and cGMP levels in the hippocampus of R6/1, R6/2 and HdhQ7/Q111 mice, and of HD patients. We also investigated
whether sildenafil, a PDE5 inhibitor, could improve cognitive deficits in R6/1 mice. We found that hippocampal cGMP
levels were 3-fold lower in 12-week-old R6/1 mice, when they show deficits in object recognition memory and in
passive avoidance learning. Consistent with hippocampal cGMP levels, nNOS levels were down-regulated, while
there were no changes in the levels of PDE5 and PDE9 in R6/1 mice. A single intraperitoneal injection of sildenafil (3
mg/Kg) immediately after training increased cGMP levels, and improved memory in R6/1 mice, as assessed by using
the novel object recognition and the passive avoidance test. Importantly, cGMP levels were also reduced in R6/2
mouse and human HD hippocampus. Therefore, the regulation of hippocampal cGMP levels can be a suitable
treatment for cognitive impairment in HD.
Citation: Saavedra A, Giralt A, Arumí H, Alberch J, Pérez-Navarro E (2013) Regulation of Hippocampal cGMP Levels as a Candidate to Treat Cognitive
Deficits in Huntington’s Disease. PLoS ONE 8(9): e73664. doi:10.1371/journal.pone.0073664
Editor: Pedro Gonzalez-Alegre, University of Iowa Carver College of Medicine, United States of America
Received April 29, 2013; Accepted July 19, 2013; Published September 5, 2013
Copyright: © 2013 Saavedra et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain (PI10/01072 to EP-N), Redes Temáticas de
Investigación Cooperativa Sanitaria (grant number RD06/0010/0006), Ministerio de Economia y Competitividad, Spain (SAF2011-29507 to JA), and
Generalitat de Catalunya, Spain (2009SGR-00326 to JA). AS and AG and are supported by Ministerio de Economia y Competitividad, Spain (Juan de la
Cierva subprograme, JCI-2010-08207 and CAPLE2009-0089, respectively). The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: estherperez@ub.edu
Introduction
Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder caused by an expanded CAG
repeat in the coding region of the huntingtin gene [1]. Although
HD is essentially a movement disorder, several evidence
indicates that cognitive impairment appears early, even before
the onset of motor symptoms, both in patients and mouse
models (reviewed in 2). The molecular events involved in this
cognitive decline are now beginning to be uncovered. For
instance, we recently demonstrated that cognitive dysfunction
in R6/1 and R6/2 mice, two exon-1 models of HD, correlates
with increased hippocampal cAMP-regulated protein kinase
(PKA) activity, and that its inhibition re-establishes recognition
memory in mutant mice, supporting the idea that PKA-
dependent processes are occluded in HD mice hippocampus
[3].
The nitric oxide/soluble guanylyl cyclase/3',5'-cyclic
guanosine monophosphate /cGMP-dependent protein kinase
(NO/sGC/cGMP/cGK) signaling pathway has been widely
implicated in synaptic plasticity, and in learning and memory in
different brain regions, including the hippocampus, cerebellum
and amygdala (reviewed in 4). NO is produced by nitric oxide
synthase (NOS) and stimulates the activity of sGC leading to
the production of cGMP [5]. In turn, cGMP can activate cGMP-
gated channels [6], modulate the activity of
phosphodiesterases (PDEs) [7], and activate cGK, with the
consequent phosphorylation of specific proteins involved in
signal transduction [8]. Importantly, cognitive loss in
Alzheimer’s disease and during aging has been associated
with a down-regulation of the NO/cGMP/cGK pathway [9].
However, the integrity of the NOS/cGMP pathway in the
hippocampus of HD mice and patients, and the potential
contribution of its alteration to learning and memory defects
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have not been addressed yet. Interestingly, neuronal NOS
(nNOS) mRNA levels are decreased in the caudate of HD
patients [10], and changes in nNOS protein levels have been
also reported in the striatum and cortex of HD mouse models
[11–15].
Phosphodiesterases (1–11) play an important role in signal
transduction by specifically catalyzing the hydrolysis of the
second messengers cAMP and/or cGMP, thereby regulating
their intracellular concentration [7]. Evidence from studies in
subjects with intact memory and in models of impaired memory
indicates that PDE inhibitors can be potentially used as
cognitive enhancers [16–21]. Importantly, treatment with
sildenafil, a selective inhibitor of the cGMP-specific PDE5 [22],
is beneficial in models of cognitive loss associated with aging
[23,24] and different pathological conditions including
Alzheimer’s disease [25–27], pre-eclampsia [28], and hepatic
encephalopathy [29].
The aim of this study was to investigate the nNOS/cGMP
pathway in the hippocampus of HD mouse models and patients
in order to determine whether it can be a good therapeutic
target to improve cognitive function in HD. Our results showed
that the nNOS/cGMP pathway is disrupted in the hippocampus
of R6 mice and in HD patients and that PDE5 inhibition may
prove to be beneficial to ameliorate cognitive deficits in HD.
Materials and Methods
HD mouse models
In this study we used male R6/1 and R6/2 heterozygous
transgenic mice (B6CBA background) expressing the exon-1 of
mutant huntingtin (mhtt) with 145 and 115 CAG repeats,
respectively [30,31], and their corresponding wild-type
littermates. Male wild-type HdhQ7/Q7 and heterozygous mutant
HdhQ7/Q111 knock-in mice were obtained from matings between
male and female HdhQ7/Q111 heterozygous as described
previously [32]. Mouse genotype and repeat length were
determined as described elsewhere [30,33,34]. All mice were
housed together in numerical birth order in groups of mixed
genotypes, and data were recorded for analysis by microchip
mouse number (Avid Identification Systems, Inc., Norco, CA).
The animals were housed with access to food and water ad
libitum in a colony room kept at 19-22°C and 40-60% humidity,
under a 12: 12 h light/dark cycle. All procedures were
performed in compliance with the National Institutes of Health
guide for the care and use of laboratory animals, and approved
by the local animal care committee of Universitat de Barcelona
(99/01), and Generalitat de Catalunya (99/1094).
Post-mortem human brain tissue
Hippocampal samples were obtained from the Neurological
Tissue Bank of the Biobank-Hospital Clínic-Institut
d’Investigacions Biomèdiques August, Pi i Sunyer (IDIBAPS;
Barcelona, Spain; URL: www.clinicbiobanc.org), and from the
Institute of Neuropathology, Hospital de Bellvitge (University of
Barcelona, Spain; URL: www.idibell.cat/modul/biobanc/en),
following the guidelines and approval of the local ethics
committee (Hospital Clínic of Barcelona’s Clinical Research
Ethics Committee). cGMP levels were analyzed in hippocampal
samples from six HD patients and five control cases. Details
are provided in Table 1.
Determination of hippocampal cGMP levels
Hippocampal cGMP levels were analyzed by using the
acetylated version of a commercially available cGMP enzyme
immunoassay kit (Sigma-Aldrich, St Louis, MO). The two
hippocampi of every mouse were pooled and lysed in 200 μl
0.1 M HCl provided in the kit. Human hippocampal tissue was
lysed in 400 μl 0.1 M HCl. Samples were sonicated and
centrifuged at 600 x g for 15 min at room temperature. The
supernatant was collected, acetylated and used according with
the manufacturer instructions.
Total protein extraction
Wild-type and R6/1 mice were killed by cervical dislocation at
the age of 8, 12, 20 and 30 weeks, and hippocampi were
quickly removed. Tissue was homogenized in lysis buffer
[50mM Tris–HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 1%
Triton X-100, 100 mM NaF, 5μM ZnCl2 and 10 mM EGTA] plus
protease inhibitors [phenylmethylsulphonyl fluoride, PMSF
(2mM), aprotinin (1μg/ml), leupeptin (1μg/ml) and sodium
Table 1. Details of control and HD human samples analyzed in the present study.
Pathological diagnosis CAG repeats Gender Age (years) Post-mortem delay (h)
None - Male 39 3:30
None - Male 64 3:30
None - Female 71 8:30
None - Female 60 15:30
None - Female 81 23:30
HD, Vonsattel grade 4 62 Female 28 4:15
HD, Vonsattel grade 4 44 Male 59 5:30
HD, Vonsattel grade 1 40 Male 73 7:00
HD, Vonsattel grade 3-4 n.d. Male 55 7:00
HD, Vonsattel grade 3 45 Male 53 7:00
HD, Vonsattel grade 3 42 Female 72 17:00
n.d., non-determined
Hippocampal nNOS/cGMP Pathway in HD
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orthovanadate (1mM)] and centrifuged at 16100xg for 20min.
The supernatants were collected and the protein concentration
was measured using the Dc protein assay kit (Bio-Rad,
Hercules, CA).
Western blot analysis
Western blot analysis was performed as previously
described [34]. The primary antibodies used were: anti-nNOS
(1:500; BD Transduction Laboratories, San Jose, CA), anti-
PDE5A and anti-PDE9A (1:500; Abcam, Cambridge, UK).
Loading control was performed by reprobing the membranes
with an anti-α-tubulin antibody (1:50000; Sigma-Aldrich) during
20min at room temperature. Then, membranes were washed
with TBS-T (Tris-buffered saline containing 0.1% Tween 20),
incubated for 1h (20 min for α-tubulin) at room temperature with
the corresponding horseradish peroxidase-conjugated
secondary antibody (1:2000; Promega, Madison, WI), and
washed again with TBS-T. Immunoreactive bands were
visualized using the Western Blotting Luminol Reagent (Santa
Cruz Biotechnology, Santa Cruz, CA) and quantified by a
computer-assisted densitometer (Gel-Pro Analyzer, version 4,
Media Cybernetics).
Sildenafil treatments
To analyze the effect of PDE5 inhibition on cognitive
function, 12-week-old wild-type and R6/1 mice received an
intraperitoneal (i.p.) injection of vehicle (water) or sildenafil (3
mg/Kg). This dose was selected based on previous studies
showing improvement in memory consolidation when sildenafil
was administered immediately after training [35–39]. Mice were
injected immediately after training in the novel object
recognition test (NORT) and in the passive avoidance test,
respectively. Memory was assessed 24 h later. The washout
period between the two memory tasks was of at least 5 days.
Another group of 12-week-old wild-type and R6/1 mice was
trained in the passive avoidance test and received an i.p.
injection of vehicle or sildenafil (3 mg/Kg) immediately after
training. Mice were sacrificed 1 h later, and the hippocampi
were quickly dissected, immediately frozen in dry ice, and
stored at -80°C until analysis of cGMP levels.
Learning and memory assessment
Learning and memory was analyzed using the NORT [40],
and the passive avoidance paradigm [41,42]. Behavioral
testing was carried out during the light phase of the animals
(ranging from 8: 00 am to 8: 00 pm) in a room maintained in the
same environmental conditions as the colony room. The NORT
was performed in 12-week-old wild-type and R6/1 mice as
previously described [3]. Briefly, mice were first habituated to
the arena (circular; 40 cm diameter x 40 cm height) in the
absence of objects (3 days, 15 min/day). On the fourth day, a
training session was performed during 10 min by presenting
two similar objects resembling eggs. Twenty-four hours later, in
the testing session, the animals were exposed for 5 min to a
familiar and a new object (resembling a cup). The object
preference was measured as the time exploring each object
(nose spokes) x 100/time exploring both objects. In order to
avoid odors, the arena was rigorously cleaned between animal
trials by flushing with 70° ethanol and allowing it to dry. The
effects of motivation, locomotor activity and anxiogenic
components on the learning task were monitored by assessing
the distance traveled and the time spent in the center of the
open field (automated SMART junior software; Panlab, Spain),
as well as the number of defecations. The passive avoidance
test is used to assess learning and memory based on the
natural preference of mice for a dark environment, and the
association between an aversive stimulus (e.g. foot shock) and
the preferred environmental context. We used the same mice
as for the NORT. The experiment was conducted in a two-
compartment device divided by a sliding door (preferred dimly
lit compartment; 2-5 Lux; in cm 25 (l) x 25 (b) x 20 (h); brightly
lit compartment; 160 Lux; in cm 20 (l) x 15 (b) x 16 (h)). The
dark chamber had a stainless steel grid floor for shock delivery.
Mice were not previously exposed to the inhibitory avoidance
apparatus. On the training day, each mouse was placed into
the brightly lit compartment facing to the opposite side of the
sliding door. Five seconds later the sliding door was open to
allow access to the dimly lit compartment, and the latency to
enter the dark compartment (step-through latency) was
registered for a maximum of 600 s. Upon entry into the
preferred dark compartment with all paws the door was closed
and mice received a mild foot shock (1 mA, 2 sec). Twenty
seconds later mice were removed from the apparatus and
returned to their home cage. Twenty-four hours later mice were
returned to the brightly lit compartment, and following a
procedure similar to that of training, except that foot shock was
omitted (retention test), the latency to enter the shock-paired
compartment was recorded for a maximum of 600 s. The
retention test was ended when mice stepped completely into
the dark compartment, or failed to cross within 600 s. In this
case they were assigned a score of 600 s. Retention latency is
an index of memory since mice that learn the task avoid the
compartment previously paired with the shock, and show
greater latency to enter the dark compartment.
Statistical analysis
All data are expressed as mean ± SEM. Statistical analysis
were performed by using the unpaired Student’s t-test (95%
confidence) or the two-way ANOVA as appropriate, and
indicated in the figure legends. Values of p<0.05 were
considered as statistically significant.
Results
cGMP levels are reduced in the hippocampus of R6/1
mice
To address whether changes in cGMP levels might
contribute to hippocampal-dependent cognitive deficits in HD
mice, we analyzed cGMP levels in the hippocampus of the
R6/1 mouse model of HD at 8 and 12 weeks of age. There
were no significant changes in cGMP levels in 8-week-old R6/1
compared with wild-type mice (t14=0.5277, p=0.6060; Figure 1).
Conversely, at 12 weeks of age, when they show memory
impairment [3], cGMP levelswere significantly reduced
compared with control littermates (t15=5.121, p<0.001; Figure
1). These results suggest that alterations in the cGMP pathway
Hippocampal nNOS/cGMP Pathway in HD
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e73664
in the hippocampus of R6/1 mice can participate in cognitive
impairment in hippocampal-dependent tasks.
nNOS levels are down-regulated in the hippocampus of
R6/1 mice
NO activates sGC, which upon activation catalyzes the
formation of cGMP. Therefore, the significant decrease in
cGMP levels in the hippocampus of R6/1 mice could be related
to reduced nNOS levels leading to a lower production of NO.
To check this possibility, we analyzed the levels of nNOS in the
hippocampus of R6/1 mice at different stages of the disease
progression. In agreement with cGMP levels (Figure 1), nNOS
protein levels were unchanged in 8-week-old R6/1 mice
compared with wild-type animals (t12=0.064, p=0.95), but there
was a dramatic reduction in nNOS levels in the hippocampus of
12-, 20- and 30-week-old R6/1 animals compared with age-
matched controls (12 weeks: t11=6.489, p<0.0001; 20 weeks:
t9=10.41, p<0.0001 and 30 weeks: t11=3.416, p=0.0058; Figure
2A).
In addition to nNOS activity, cGMP levels can also be
modulated by PDEs [7]. For this reason, we next analyzed the
protein levels of different PDEs, focusing on cGMP-specific
PDEs expressed in the hippocampus, PDE5A and PDE9A
[43,44]. PDE5A protein levels were unchanged in R6/1 mice at
Figure 1.  cGMP levels in the hippocampus of R6/1
mice.  Hippocampal cGMP levels were analyzed in wild-type
(WT) and R6/1 mice at 8 and 12 weeks of age by enzyme
immunoassay. Values are expressed as percentage of WT
mice, and are the mean ± SEM (n=7-10). Data were analyzed
by Student’s t-test. ***p<0.001 as compared with age-matched
WT mice.
doi: 10.1371/journal.pone.0073664.g001
12 (t11=0.849, p=0.413) and 20 (t14=1.137, p=0.274) weeks of
age, and were significantly reduced compared to wild-type
animals only at 30 weeks of age (t21=2.642, p=0.015) (Figure
2B). In contrast, PDE9A protein levels were not altered in the
hippocampus of R6/1 mice compared with littermate controls at
any of the ages analyzed (Figure 2C). These findings indicate
that changes in PDE5A and PDE9A levels do not contribute to
the reduction of cGMP levels in the hippocampus of 12-week-
old R6/1 mice, and that the down-regulation of nNOS is likely
the major contributor to reduced hippocampal cGMP levels in
the presence of N-terminal exon-1 mhtt.
Sildenafil treatment increases hippocampal cGMP
levels and improves memory in R6/1 mice
The severe down-regulation of cGMP levels in the
hippocampus of R6/1 mice (Figure 1) when cognitive
impairment in hippocampal-dependent tasks is evident [3] lead
us to hypothesize that pharmacological modulation of cGMP
levels could ameliorate cognitive dysfunction in these mice. To
address our hypothesis, wild-type and R6/1 mice received an
i.p. injection of sildenafil (3 mg/Kg) or vehicle after training in
the NORT and passive avoidance test, respectively, and
memory was assessed 24 h later. In the NORT, during the
training session, there were no differences in the time spent
exploring the two objects (data not shown). Conversely, and as
previously reported [3], R6/1 mice showed memory deficits
(genotype effect: F(1,33)=14.32, p=0.0006) as indicated by their
lower preference for the novel object as compared with wild-
type mice (Figure 3A). In contrast, sildenafil-treated R6/1 mice
showed a higher preference for the new object than vehicle-
treated R6/1 animals (treatment effect: F(1,33)=10.49, p=0.0027),
and were indistinguishable from wild-type vehicle-treated mice
(Figure 3A). Sildenafil treatment also improved memory in wild-
type mice (t=2.469, p<0.05) (Figure 3A). No significant
differences were observed in motor activity or anxiety levels
during memory assessment (Table 2), indicating that
alterations in spontaneous locomotor activity or anxiety levels
were unlikely to affect the performance of sildenafil-treated
mice in the NORT.
In the passive avoidance test, we found that the step-through
latency during the training session was higher in R6/1 than in
wild-type animals (genotype effect: F(1,34)=13.83, p=0.0007)
(Figure 3B). In the testing session, vehicle-injected R6/1 mice
showed a lower latency to step into the compartment
previously paired with the shock than wild-type vehicle-treated
mice (genotype effect: F(1,33)=8.791, p=0.0056) (Figure 3B).
This finding indicated that R6/1 mice suffer memory deficits in
avoidance learning. In contrast, sildenafil-treated R6/1 mice
showed a recall latency indistinguishable from vehicle-treated
wild-type mice (Figure 3B), which further supports the idea that
sildenafil treatment improves memory in mutant mice. In this
paradigm we did not find improvement in wild-type mice
receiving sildenafil treatment after training (t=0.032, p>0.05)
probably because vehicle-treated animals already performed
near the threshold (Figure 3B).
Next, we sought to determine whether memory improvement
found in sildenafil-treated R6/1 mice was related to higher
cGMP levels following training that could contribute to memory
Hippocampal nNOS/cGMP Pathway in HD
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Figure 2.  nNOS, PDE5A and PDE9A levels in the hippocampus of R6/1 mice.  nNOS (A), PDE5A (B) and PDE9A (C) protein
levels were analyzed by Western blot of protein extracts obtained from the hippocampus of 8- to 30-week-old wild-type (WT) and
R6/1 mice. Representative immunoblots are shown. Values (obtained by densitometric analysis of Western blot data) are expressed
as percentage of WT mice, and shown as mean ± SEM (n=5-8 in A, n=5-12 in B and n=5-7 in C). Data were analyzed by Student’s
t-test. *p<0.05, **p<0.01 and ***p<0.001 as compared with age-matched WT mice.
doi: 10.1371/journal.pone.0073664.g002
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Figure 3.  Memory is improved in sildenafil-treated R6/1 mice.  Twelve-week-old wild-type (WT) and R6/1 mice received an i.p
injection of sildenadil (3 mg/Kg) or vehicle immediately after training for the NORT (A) and the passive avoidance test (B),
respectively (n=7-11). Preference for the new object in the NORT (A) and for the brightly lit compartment in the passive avoidance
test (B) was quantified 24 h after the training session. A different cohort of mice (n=4-5) was trained for the passive avoidance test,
received an i.p. injection of sildenadil (3 mg/Kg) or vehicle immediately after, and was sacrificed 1 h later to determine hippocampal
cGMP levels (C). Bars represent the mean ± SEM. Data were analyzed by two-way ANOVA with Bonferroni as a post hoc test.
*p<0.05 as compared with WT vehicle-treated mice; $p<0.05 as compared with R6/1 vehicle-treated mice and #p<0.05 as
compared with WT sildenafil-treated mice (A). *p<0.05 as compared with latency to step through during training in WT mice groups;
& p<0.05 as compared with latency to step through during training and † p<0.05 as compared with latency to step through during
testing in WT vehicle-treated mice (B). **p<0.01 as compared with WT vehicle-treated mice, and $p<0.05 as compared with R6/1
vehicle-treated mice (C).
doi: 10.1371/journal.pone.0073664.g003
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consolidation in mutant mice. To this end, wild-type and R6/1
mice were trained in the passive avoidance test, received an
i.p. injection of vehicle or sildenafil (3 mg/Kg) immediately after
training, and were sacrificed 1 h later to determine
hippocampal cGMP levels. We found that cGMP levels were
lower in vehicle-treated R6/1 mice compared with vehicle-
treated wild-type animals, and that treatment with sildenafil
after training increased cGMP levels in both genotypes (Figure
3C). Summarizing, this set of results indicates that increasing
hippocampal cGMP levels rescues memory deficiencies in
R6/1 mice, and that this can be a good therapeutic target to
fight cognitive decline in HD.
cGMP levels are also reduced in the hippocampus of
R6/2 mice and HD patients
We next analyzed if the reduction of cGMP levels found in
R6/1 mice hippocampus could be replicated in other HD mouse
models when they show cognitive deficits. For this we
examined R6/2 mice, which also express N-terminal exon-1
mhtt but show earlier onset and more severe phenotype than
R6/1 mice [33], and HdhQ7/Q111 mice, which show late onset and
slow progression of the disease [31]. As observed in R6/1
mice, we found that at 9-11 weeks, when R6/2 mice suffer from
memory impairment [3], hippocampal cGMP levels were
significantly reduced compared with age-matched controls
(t13=2.538, p=0.0247) (Figure 4A). In contrast, we did not
observe significant changes in cGMP levels in the
hippocampus of 8-month-old HdhQ7/Q111 mice compared with
age-matched controls (t11=1.732, p=0.1112) (Figure 4B).
Finally, we quantified cGMP levels in hippocampal samples
from control subjects and HD patients. We found that cGMP
levels were significantly reduced in postmortem hippocampal
samples from HD patients compared with control subjects
(t9=2.452, p=0.0366) (Figure 4C). These results indicate that
reduced cGMP levels can contribute to cognitive impairment
and that targeting this pathway might also lead to cognitive
improvement in HD patients, while cognitive deficits in 8-
month-old HdhQ7/Q111 mice [45] are unlikely to be related to
alterations in hippocampal cGMP levels.
Discussion
In this work we show for the first time that the nNOS/cGMP
pathway is severely down-regulated in the hippocampus of
R6/1 mice, and that PDE5 inhibition improves memory deficits
in these animals. Importantly, we also detected decreased
levels of cGMP in the hippocampus of R6/2 mice and HD
patients, leading us to propose PDE5 inhibition as a therapy to
fight cognitive decline in HD.
We detected reduced cGMP levels in the hippocampus of
R6/1 mice at 12, but not at 8, weeks of age. Changes in cGMP
levels could result from altered synthesis by sGC or increased
degradation by PDEs, but we did not detect changes in the
protein levels of the cGMP-specific PDE5A and PDE9A in the
hippocampus of R6/1 mice at this age. Since we found that, in
correlation with cGMP levels, nNOS levels were reduced in
12-, but not in 8-week-old R6/1 mice hippocampus, the
alterations in cGMP levels are likely related to diminished
nNOS levels, lower NO production and consequent reduced
cGMP synthesis by sGC. The finding that nNOS levels were
significantly reduced in the hippocampus of R6/1 mice
indicates that the levels of this protein are sensitive to the
presence of mhtt in several brain regions as nNOS protein
levels/NOS activity are also down-regulated in the striatum and
cortex of R6 mice [11,14].
We and others have reported that R6/1, R6/2 and HdhQ7/Q111
HD mouse models show object recognition impairment before
motor symptoms develop [3,45,46]. Moreover, R6/2 mice
display impaired performance in the passive avoidance test
[47]. Here, we show that object recognition memory and
passive avoidance learning deficits correlate with reduced
hippocampal cGMP levels in R6 mice. Accumulating evidence
indicates that the activation of the NO/sGC/cGMP/cGK
Table 2. Anxiety and locomotor activity assessment during the NORT in wild-type and R6/1 mice treated with vehicle or
sildenafil.
 Group Day 1 Day 2 Day 3 Training trial Testing trial
Defecations WT vehicle 3.24±0.72 3.10±0.84 2.00±0.22 3.10±1.52 2.32±0.24
 R6/1 vehicle 2.99±2.21 3.40±0.74 3.2±1.33 2.22±0.99 3.11±1.32
 WT sildenafil 3.31±2.10 4.72±0.97 4.2±1.49 3.23±1.08 2.76±1.33
 R6/1 sildenafil 3.00±0.22 3.92±0.41 4.0±0.33 3.69±1.51 3.22±1.40
Time in center (%) WT vehicle 29.55±2.69 31.17±5.12 31.23±7.55 13.32±4.27 19.31±2.88
 R6/1 vehicle 41.01±7.55 26.41±9.38 33.92±7.66 15.88±5.77 15.65±7.99
 WT sildenafil 32.23±2.22 24.04±6.22 28.55±3.05 14.23±8.11 22.25±6.36
 R6/1 sildenafil 35.75±9.33 25.94±6.81 27.44±6.45 16.55±5.97 25.44±4.54
Distance traveled (cm) WT vehicle 4525±323 3775±393 3444±252 2223±363 1923±222
 R6/1 vehicle 3800±298 3383±303 2955±422 2099±525 1714±193
 WT sildenafil 4350±234 3815±412 3221±331 3012±495 2013±432
 R6/1 sildenafil 4185±334 3292±368 2978±522 2168±356 1982±297
The number of defecations, time spent in the center of the open field and the distance traveled were analyzed during the NORT in wild-type (WT) and R6/1 mice treated with
vehicle or sildenafil (3 mg/Kg) immediately after training. Day 1-3 correspond to habituation. Values are shown as mean ± SEM. For each parameter data were analyzed by
two-way ANOVA.
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Figure 4.  cGMP levels in the hippocampus of HD mice and
patients.  Hippocampal cGMP levels were analyzed by
enzyme immunoassay of samples obtained from 9- to 11-
week-old wild-type and R6/2 mice (A), 8-month-old HdhQ7/Q7
and HdhQ7/Q111 mice (B), and control subjects and HD patients
(C). Values are expressed as percentage of control mice (A
and B; n=6-8) and subjects (C; n=5-6), respectively, and are
the mean ± SEM. Data were analyzed by Student’s t-test.
*p<0.05 as compared with the control.
doi: 10.1371/journal.pone.0073664.g004
signaling cascade is important during the early phase of
memory consolidation. For example, infusion of the cGMP
analog 8-Br-cGMP just after the first trial improves memory
performance in the object recognition test [48], and in the
inhibitory avoidance test [49], while inhibition of nNOS, sGC or
cGK impairs object recognition [50]. In addition, hippocampal
NOS activity [51], cGMP levels [49,52], and cGK activity [52]
increase immediately after training for inhibitory avoidance
learning. Thus, the fact that reduced cGMP levels in R6 mice
correlate with cognitive deficits suggests an involvement of this
pathway in this phenomenon. In contrast, since we did not
detect differences in hippocampal cGMP levels between 8-
month-old HdhQ7/Q111 and wild-type mice, alterations in cGMP
signaling are likely not participating in memory impairment
reported in mutant mice [45]. However, we cannot rule out that
this pathway might be affected in older animals. The lack of
changes in cGMP levels is consistent with the finding that
hippocampal nNOS levels were not altered in 8-month-old
HdhQ7/Q111 compared with wild-type mice (data not shown).
Cortical and striatal nNOS levels undergo a biphasic
dysregulation in exon-1 mouse models, with increased levels/
activity at early/middle stages followed by a reduction at later
stages of the disease progression [13,14]. Thus, it is likely that
the late onset and slow progression of the disease in HdhQ7/Q111
mice compared with exon-1 models contributes to these
differences.
Importantly, in the present study we showed that memory
deficits in object recognition and in the passive avoidance test
in R6/1 mice were rescued by the post-training injection of
sildenafil. In addition, sildenafil treatment also increased object
recognition memory in wild-type mice. Likewise, previous
studies have shown that administration of sildenafil, or other
PDE5 inhibitors, improves object recognition both in normal
subjects, and in models of impaired cognition (reviewed in 18),
and ameliorates inhibitory avoidance response in mice showing
deficits in this task [53,54]. In contrast, sildenafil-induced
memory improvement is abolished in animals receiving an
intra-hippocampal infusion of a cGK inhibitor [27,37]. The
finding that sildenafil increases cGMP levels and improves
novel object recognition memory and passive avoidance
learning in R6/1 mice further supports the idea that decreased
hippocampal cGMP levels contribute to cognitive dysfunction in
these mice.
In addition to the hippocampus (present results and [55,56]),
it is noteworthy that sildenafil also increases cGMP levels in the
cortex [55,57] and striatum [56], and that PDE5 inhibition
improves the performance in cognitive tasks involving these
brain regions, both in unimpaired subjects and in models of
impaired memory (reviewed in 18). Moreover, it increases NOS
activity in the striatum and cortex [58], which might be relevant
in the context of HD, as nNOS mRNA levels are decreased in
the caudate of HD patients [10]. It is also worthy to mention
that treatment with sildenafil restores cGMP levels in
pathological situations associated with reduced cGMP in the
brain [28,29], improves memory in mouse models of
Alzheimer’s disease [25–27], and ameliorates age-related
cognitive decline [23,24]. Importantly, it has been recently
shown in patients with erectile dysfunction that treatment with a
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PDE5 inhibitor improves cognitive function [59]. The finding
that hippocampal cGMP levels are decreased in R6 mice, and
in human HD hippocampus, together with previous results
indicating that nNOS pathway is also highly affected in the
striatum and cortex of HD mice [11–15], suggests that PDE5
inhibition can be a good therapeutic strategy for cognitive
improvement in HD.
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